Feldman and Schor explain that the patent dance is a complex process to determine which of a biologic manufacturer’s patents ...

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara ...

Accelerate Polpharma Biologics biosimilar program from IND to commercial manufacturing Includes a commitment to producing for US FDA BLA submission Expand global market presence through launch in ...

As per the latest analysis, the biosimilar and biologics market value is estimated to reach USD 520.9 billion in 2024. Global sales of biosimilars and biologics will likely increase at 7.6% CAGR ...

It now boasts approvals for nine indications including rheumatoid arthritis and related conditions ... in an earlier debate about biosimilars' impact on the biologic drug market were correct.

Ivo Abraham, PhD, highlights follow-on biologics as a pathway to a more equitable global health care system by reducing costs ...

From the creation of a regulatory pathway for biosimilars in the EU only three biologics experienced EU biosimilar competition until the launch of Remsima/Inflectra in 2013, and none have (as at ...

Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes ...

BRIDGEWATER, N.J. and BENGALURU, Karnataka, India, April 15, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars ... age-related macular degeneration, visual ...

This week, CuraTeQ Biologics (a wholly owned step-down subsidiary of Aurobindo Pharma Limited) announced that its trastuzumab biosimilar, DAZUBLYS, has received a positive opinion from the ...

announced a strategic cooperation agreement with Polpharma Biologics to advance the end-to-end development and manufacture of a biosimilar product for the global market. This partnership underscores ...